New leading-edge technology produces higher yields of stem cells to enhance patient treatments
HOUSTON, Aug. 21, 2019 /PRNewswire/ — Tissue Genesis, a leading developer of cell therapy processing systems, announced today that an initial group of patients was successfully treated in the first clinical application of its Icellator® X technology at the Okyanos Center for Regenerative Medicine in Freeport, Bahamas. The new fully enclosed and automated system generated a higher yield of stem cells from adipose (fat) tissue than had been previously possible.
https://www.tissuegenesis.com/wp-content/uploads/2019/08/IcellatorX-delivers-results-08-21-19.jpg6751200Tissue Genesishttps://www.tissuegenesis.com/wp-content/uploads/2018/06/TG-logo.svgTissue Genesis2019-08-21 16:05:222019-08-21 16:05:22Tissue Genesis' Icellator® X Delivers Results in First Clinical Application
Study to investigate whether adipose-derived SVF therapy can reduce amputation, speed up wound healing and increase ambulatory function.
HOUSTON (March 26, 2019) — Tissue Genesis, LLC, the leading provider of cell isolation technology is pleased to announce that the Icellator® is being used to generate therapeutic cell preparations at the V.P. Komisarenko Institute of Endocrinology and Metabolism in Kiev, Ukraine, for patients with critical limb ischemia (CLI). The autologous stem-cell therapy, which utilizes a patient’s own fat cells, is the first of its kind in Ukraine to treat CLI patients. This effort will build on previous stem cell studies that have shown promising results as a potential therapeutic option for this debilitating and increasingly common vascular disease.
The enhanced enzyme-derived stem cell isolation system offers a greater overall impact and efficiency in the field of regenerative medicine
Houston (December 11, 2018) – Tissue Genesis LLC announced today the release of the Icellator® X, the newest and most advanced system for isolating stem cells in adipose tissue.
The Icellator® X expands on the capabilities of the original Icellator®, representing a major advancement in the real-world application of stem therapies for patients.
The new-to-market Icellator® X offers greater stem cell yields, improved ease of use, and a user interface available in multiple languages. It is immediately the most efficient system available on the market. The 2019 Icellator® X lets medical professionals and scientists rapidly recover millions of a patient’s own adult stem cells for therapeutic treatments and research applications.
HOUSTON (Nov. 1, 2017) – Human Life CORD Japan, Inc., (HLC) a group company of Nihon Trim (Cord No. 6788, Tokyo Stock Exchange 1st Section) is pleased to announce a strategic agreement with Tissue Genesis, LLC (TG) to distribute its proprietary stem cell processing products in commercial clinics, research institutions, and hospitals in Japan and China. Read more
https://www.tissuegenesis.com/wp-content/uploads/2017/11/news-icellator.jpg6691000Tissue Genesishttps://www.tissuegenesis.com/wp-content/uploads/2018/06/TG-logo.svgTissue Genesis2017-11-01 13:13:532018-11-13 16:21:53TG & Human Life CORD, Japan Announce Exclusive Partnership
Tissue Genesis’ Icellator® X Delivers Results in First Clinical Application
/in News, Regenerative Medicine, Stem Cells, Tissue Genesis /by Tissue GenesisNew leading-edge technology produces higher yields of stem cells to enhance patient treatments
HOUSTON, Aug. 21, 2019 /PRNewswire/ — Tissue Genesis, a leading developer of cell therapy processing systems, announced today that an initial group of patients was successfully treated in the first clinical application of its Icellator® X technology at the Okyanos Center for Regenerative Medicine in Freeport, Bahamas. The new fully enclosed and automated system generated a higher yield of stem cells from adipose (fat) tissue than had been previously possible.
Read more
Tissue Genesis, LLC Provides Cell Isolation Processing for Patients with Critical Limb Ischemia (CLI) in Ukrainian Clinical Study
/in News, Regenerative Medicine, Stem Cells, Tissue Genesis /by Tissue GenesisStudy to investigate whether adipose-derived SVF therapy can reduce amputation, speed up wound healing and increase ambulatory function.
HOUSTON (March 26, 2019) — Tissue Genesis, LLC, the leading provider of cell isolation technology is pleased to announce that the Icellator® is being used to generate therapeutic cell preparations at the V.P. Komisarenko Institute of Endocrinology and Metabolism in Kiev, Ukraine, for patients with critical limb ischemia (CLI). The autologous stem-cell therapy, which utilizes a patient’s own fat cells, is the first of its kind in Ukraine to treat CLI patients. This effort will build on previous stem cell studies that have shown promising results as a potential therapeutic option for this debilitating and increasingly common vascular disease.
Read more
Tissue Genesis Introduces State-of-the-Art Icellator® X
/in News, Tissue Genesis /by Jeremy CargillThe enhanced enzyme-derived stem cell isolation system offers a greater overall impact and efficiency in the field of regenerative medicine
Houston (December 11, 2018) – Tissue Genesis LLC announced today the release of the Icellator® X, the newest and most advanced system for isolating stem cells in adipose tissue.
The Icellator® X expands on the capabilities of the original Icellator®, representing a major advancement in the real-world application of stem therapies for patients.
The new-to-market Icellator® X offers greater stem cell yields, improved ease of use, and a user interface available in multiple languages. It is immediately the most efficient system available on the market. The 2019 Icellator® X lets medical professionals and scientists rapidly recover millions of a patient’s own adult stem cells for therapeutic treatments and research applications.
Read more
TG & Human Life CORD, Japan Announce Exclusive Partnership
/in News, Regenerative Medicine, Stem Cells, Tissue Genesis /by Tissue GenesisHOUSTON (Nov. 1, 2017) – Human Life CORD Japan, Inc., (HLC) a group company of Nihon Trim (Cord No. 6788, Tokyo Stock Exchange 1st Section) is pleased to announce a strategic agreement with Tissue Genesis, LLC (TG) to distribute its proprietary stem cell processing products in commercial clinics, research institutions, and hospitals in Japan and China. Read more